Dr. Jacqueline Huang was invited to be the keynote speaker for the course "Business Valuation of Biopharmaceutical Enterprises" 黄玮博士受邀担任「香港生物医药技术培训——生物医药企业的商业评估」课程主题讲者

2024年8月，黃瑋博士受邀擔任由生物醫藥創新協會主辦、香港生產力促進局執行的「香港生物醫藥技術培訓-生物醫藥企業的商業評估」課程的主題講者。黃瑋博士就生物醫藥企業商業開發中的估值展開話題，涵蓋了企業商業開發的準備及一般週期、商業化路徑、成功商業開發的關鍵要素等內容。黃瑋博士由此引入主題，詳細介紹了商業開發中的估值方法，評估常見的用途，並簡要分享了生物醫藥企業在香港上市的條件。黃博士也對目前生物醫藥企業的主要特性及評估過程中的核心難題進行了深入解析，強調生物科技公司評估應根據各企業的內部和外部因素進行具體分析。

此外，黃瑋博士分享了多種適用於生物科技公司不同生命週期的估值模型，重點解析了收益法並指出其中的關注重點及估值調整方法，以一家致力於創新藥品開發的生物醫藥企業為案例詳細說明了管線法的具體估值過程及相關假設，並在課程的最後進行了多樣化的互動環節。

In August 2024, Dr. Jacqueline Huang was invited to be the keynote speaker of the course "Hong Kong Biopharmaceutical Technology Training—Business Valuation of Biopharmaceutical Enterprises" hosted by the HK Bio-Med Innotech Association and implemented by the Hong Kong Productivity Council. Dr. Jacqueline Huang started the topic of valuation in the commercialization of biopharmaceutical enterprises, covering the preparation and general cycle of Biopharmaceutical Enterprises commercialization, commercialization path, key elements of successful commercialization, etc. Dr. Huang then introduced the main topic and gave a detailed introduction to the valuation methods in commercialization, common purposes of valuation, and briefly shared the conditions for biopharmaceutical companies to be listed in Hong Kong. Dr. Huang also conducted an in-depth analysis of the main characteristics of current biopharmaceutical companies and the core difficulties in the valuation process, emphasizing that the valuation of biopharmaceutical companies should be specifically analyzed based on the internal and external factors of each company.

In addition, Dr. Jacqueline Huang shared a variety of valuation models applicable to different life cycles of biotech companies, focusing on the analysis of the income method and pointing out the focus and valuation adjustment methods. She used a biopharmaceutical company dedicated to the development of innovative drugs as an example to explain in detail the specific valuation process and related assumptions of the pipeline method, and conducted a variety of interactive sessions at the end of the course.